Dr. Yardley on the APHINITY Trial for HER2-Positive Breast Cancer
Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the APHINITY trial investigating pertuzumab (Perjeta) for patients with adjuvant HER2-positive breast cancer.
Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the APHINITY trial investigating pertuzumab (Perjeta) for patients with adjuvant HER2-positive breast cancer.
The design of the APHINITY trial was either an anthracycline-based regimen for node-positive patients, chemotherapy with a trastuzumab (Herceptin)-based regimen for node-negative patients, or pertuzumab in combination with trastuzumab, explains Yardley.
Overall, this study has shown positive results of pertuzumab in the adjuvant setting for patients with HER2-positive breast cancer, states Yardley.
